Pipeline

Using our key technologies, we are developing novel therapeutics
to treat a variety of refractory diseases. Our SPiDEM™ technology
enables us to develop small molecules that degrade target proteins.
The SPiDEM™-based small molecules can target and
eliminate protein aggregates as well as inflammatory proteins. These small molecules are also capable of penetrating the blood-brain barrier.
We are therefore taking advantage of the features of our SPiDEM™ technology to develop therapeutics for the treatment of neurodegenerative diseases and refractory inflammatory diseases. In addition, we are also
using our SPiDEM™ technology to develop new therapeutics to treat viral diseases by targeting host factors.